New ASTRO/ASCO/AUA guideline for prostate cancer supports shortened radiation therapy

October 11, 2018, American Society for Radiation Oncology

Three prominent medical societies today issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external beam radiation therapy (EBRT). Adoption of the guideline could make treatment shorter and more convenient for many patients with prostate cancer, the most common malignancy among American men.

Developed by a panel of experts from the American Society for Radiation Oncology (ASTRO), American Society of Clinical Oncology (ASCO) and American Urological Association (AUA), the new guideline recommends offering a option known as hypofractionated as an alternative to longer, conventional courses of radiation. ASTRO, ASCO and AUA published the guideline in their respective journals, Practical Radiation Oncology, Journal of Clinical Oncology and The Journal of Urology.

"Conclusive evidence from several large, well-designed randomized trials now confirms that dose escalation can almost universally benefit men with early-stage prostate cancer who choose to manage their disease with external radiation," said Howard Sandler, MD, FASTRO, FASCO, chair and professor of radiation oncology at Cedars-Sinai Medical Center and co-chair of the guideline panel. "Significant advances in treatment planning and delivery have enabled oncologists to deliver more powerful, life-saving doses of radiation in fewer visits and without compromising quality of life."

External beam radiation therapy is a standard definitive treatment option that confers outcomes equivalent to radical prostatectomy for men with localized prostate cancer. When EBRT is hypofractionated, patients receive larger radiation doses across fewer treatment sessions—typically completing treatment in four to five weeks, compared with eight to nine weeks for conventional radiation. Extremely hypofractionated courses, also known as ultrahypofractionation, stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR), can be completed in as few as five treatments.

The recommendations apply to patients who require or prefer treatment instead of surveillance and have opted for EBRT instead of radical prostatectomy, brachytherapy or other treatment options for localized prostate cancer. Key recommendations are as follows:

  • For men who have opted for EBRT, moderate hypofractionation (fraction size of 240-340 centigray (cGy)) should be offered as an alternative to conventional fractionation (180-200 cGy) regardless of cancer risk group, patient age, comorbidity, anatomy or baseline urinary function.
    • Suggested regimens for moderate hypofractionation include the two schedules used with the largest number of patients in randomized clinical trials: 6,000 cGy delivered in 20 fractions of 300 cGy over four weeks, or 7,000 cGy delivered in 28 fractions of 250 cGy over five and a half weeks.
    • While moderately hypofractionated EBRT confers similar early cancer control and side effects to conventional fractionation, physicians should counsel patients about a small increased risk of short-term gastrointestinal toxicity and discuss how data are limited for oncologic outcomes beyond five years post-treatment.
  • Ultrahypofractionation (≥500 cGy) guidance varies by prostate-cancer risk: for low-risk patients who have opted for EBRT, it may be offered as an alternative to conventional fractionation; for intermediate-risk disease, it may be offered, but the strongly encourages treating these patients as part of a clinical trial or multi-institutional registry; for high-risk disease, the panel does not suggest offering ultrahypofractionation outside of a trial or registry. Recommendations for ultrahypofractionation were graded by the panel as "conditional," reflecting the limited base of current evidence on this approach.
    • Suggested regimens for ultrahypofractionation include the two schedules used most commonly in published studies: 3,500 cGy in five fractions of 700 cGy, or 3,625 cGy in five fractions of 725 cGy. For five-fraction regimens, the expert panel recommends against total radiation doses larger than 3,625 cGy outside of clinical trials or registries. Consecutive daily treatments also should be avoided when using five fractions.
  • Recommendations also address the technical aspects of planning and delivering hypofractionated prostate radiation, including target and normal tissue volumes, dose constraints, margin definitions and delivery techniques. The expert panel universally recommends the use of image-guided radiation therapy (IGRT) and avoidance of non-modulated conformal techniques.
  • Fraction sizes between 340 and 500 cGy have been examined in very few studies and were therefore outside the scope of the guideline. Also excluded from the current guideline are treatment for locally advanced or metastatic disease, post-operative radiation, salvage therapy and re-irradiation.

"Men who opt to receive hypofractionated radiation therapy will be able to receive a shorter course of treatment, which is a welcomed benefit to many men. When clinicians can reduce overall treatment time while maintaining outcomes, it's to our patients' benefit, as they can spend less time away from family and less time traveling to and from treatment," said Scott Morgan, MD, FRCPC, assistant professor of at the University of Ottawa and co-chair of the guideline panel.

"Image guidance and other advances in radiation therapy delivery have enabled radiation oncologists to treat with a therapeutic dose of in a shorter treatment period than was previously possible," said Daniel Barocas, MD, associate professor of urology at Vanderbilt University Medical Center and guideline co-author. "Results so far show comparable early cancer control to conventional fractionation, while maintaining an acceptable side effect profile. This has benefits to the patient in terms of reducing the treatment burden and cost, and may increase the acceptability of therapy."

To develop this guideline, a 16-member expert panel of clinicians, researchers and a patient advocate reviewed studies published from December 2001 through March 2017; sixty-one articles, including four large prospective randomized clinical trials with more than 6,000 patients, were evaluated. The guideline was approved by the ASTRO, ASCO and AUA Boards of Directors following a period of public comment. It has been endorsed by the Society of Urologic Oncology (SUO), the European Society for Radiotherapy and Oncology (ESTRO) and the Royal Australian and New Zealand College of Radiologists (RANZCR).

Explore further: ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer

More information: Scott C. Morgan et al, Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline, Practical Radiation Oncology (2018). DOI: 10.1016/j.prro.2018.08.002

Related Stories

ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer

March 28, 2017
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer. The update provides ...

Dose-escalated hypofractionated IMRT, conventional IMRT for prostate cancer have like side effects

April 3, 2014
Dose-escalated intensity modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4 Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late ...

ASTRO issues clinical guideline for whole breast radiation therapy

March 12, 2018
The American Society for Radiation Oncology (ASTRO) today issued a new clinical guideline for the use of whole breast radiation therapy for breast cancer that expands the population of patients recommended to receive accelerated ...

Shortened radiation therapy offers similar quality of life for low-risk prostate cancer patients

September 26, 2016
Low-risk prostate cancer patients may be able to undergo a shortened course of radiation therapy that cuts treatment by weeks and offers comparable outcomes and quality of life results as those who undergo longer treatment ...

ASTRO issues guideline on definitive and adjuvant RT for locally advanced non-small cell lung cancer

May 5, 2015
The American Society for Radiation Oncology (ASTRO) is issuing a new guideline, "Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based ...

Radiation therapy continues to be gold standard to palliate painful bone metastases

February 14, 2017
The American Society for Radiation Oncology (ASTRO) recently published an updated clinical guideline that underscores the safety and effectiveness of palliative radiation therapy (RT) for treating painful bone metastases. ...

Recommended for you

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Delving where few others have gone, leukemia researchers open new path

October 15, 2018
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could ...

3-D mammography detected 34% more breast cancers in screening

October 15, 2018
In traditional mammography screening, all breast tissue is captured in a single image. Breast tomosynthesis, on the other hand, is three-dimensional and works according to the same principle as what is known as tomography. ...

More clues revealed in link between normal breast changes and invasive breast cancer

October 15, 2018
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process—changes in mammary glands to accommodate breastfeeding—uses a molecular process believed ...

Cancer stem cells use 'normal' genes in abnormal ways

October 12, 2018
CDK1 is a "normal" protein—its presence drives cells through the cycle of replication. And MHC Class I molecules are "normal" as well—they present bits of proteins on the surfaces of cells for examination by the immune ...

Obesity linked to increased risk of early-onset colorectal cancer

October 12, 2018
Women who are overweight or obese have up to twice the risk of developing colorectal cancer before age 50 as women who have what is considered a normal body mass index (BMI), according to new research led by Washington University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.